Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer
Anya M. Litvak(Johns Hopkins Hospital), Roisín M. Connolly(Johns Hopkins University), Leisha A. Emens(Johns Hopkins University), John H. Fetting(Johns Hopkins University), Antonio C. Wolff(Johns Hopkins University), Raquel Silhy(Johns Hopkins University), Hua‐Ling Tsai(Johns Hopkins University), Bhavina Batukbhai(Sinai Hospital), Stuart D. Russell(Duke Medical Center), Vered Stearns(Johns Hopkins University), Deborah K. Armstrong(Johns Hopkins University), Stacie C. Jeter(Johns Hopkins University), Gary L. Rosner(Johns Hopkins University)
Cited by 91
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)
|Archives of Pathology & Laboratory Medicine|2010|1.1k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947